ABOS — Acumen Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Acumen Pharmaceuticals Secures $50.0 Million Credit Facility With K2 Healthventures
Brief: Acumen Pharmaceuticals, Inc. Q3 Income From Operations USD -16.039 Million
Brief: Acumen Pharmaceuticals, Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE Technology
Brief: Halozyme, Acumen Pharmaceuticals Enter Non-Exclusive License Agreement for ENHANZE Technology in Alzheimer's Disease
Brief: Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement
Brief: Acumen Pharmaceuticals To Present Deeper Insights From First-In-Human Phase 1 Study Of Acu193 For Early Alzheimer's
Brief: Acumen Pharmaceuticals, Inc. Q2 Income From Operations USD -13.478 Million
Brief: Acumen Announces Pricing Of Upsized $130 Million Public Offering
Acumen slides on planned equity raise to fund Alzheimer's drug development
Brief: Acumen Pharmaceuticals Says As Of June 30, 2023, Cash And Cash Equivalents And Marketable Securities Were About $172.2 Mln
U.S. STOCKS ON THE MOVE-Argenx, ViewRay, Ford
Acumen Pharma jumps as Alzheimer's drug well-tolerated in early-stage study
U.S. STOCKS ON THE MOVE-Activision Blizzard, Tesla, Paramount Global
Acumen Pharma soars after Alzheimer's drug well-tolerated in early stage study
Brief: Acumen Pharmaceuticals Says Presents Positive Topline Results From First-In-Human Phase 1 Study Of ACU193 For Early Alzheimer's Disease
Acumen's Alzheimer's drug passes initial safety test
Eli Lilly falls after rival Alzheimer's drug gets full approval with warning
Brief: Acumen Pharmaceuticals Reports Q1 2023 Financial Results And Business Highlights
Brief: Acumen Pharmaceuticals Enters Into Amendment To Sales Agreement